Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | APP | P05067 | 1/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
| ▸ | F3 | P13726 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5403708 | 1.00 | LMNA (0.62) | LMNATDP1APPGSK3BFLT3 | |
| Acrylic Acid SCHEMBL2498158 | 0.94 | THRB (0.59) | LMNATDP1APPGSK3BFLT3 | |
| SCHEMBL5259319 | 0.86 | LMNA (0.63) | LMNATDP1GSK3BF3SMN1; SMN2 | |
| SCHEMBL14560098 | 0.85 | GSK3B (0.56) | LMNATDP1GSK3BFLT3F3 | |
| SCHEMBL7092085 | 0.85 | LMNA (0.67) | LMNATDP1GSK3BFLT3F3 | |
| SCHEMBL11820773 | 0.84 | APP (0.64) | LMNAAPPSMN1; SMN2KMT2AMAPT | |
| SCHEMBL9855983 | 0.84 | LMNA (0.68) | LMNATDP1GSK3BF3SMN1; SMN2 | |
| SCHEMBL9855976 | 0.84 | LMNA (0.68) | LMNATDP1GSK3BF3SMN1; SMN2 | |
| SCHEMBL8148439 | 0.84 | LMNA (0.68) | LMNATDP1GSK3BF3SMN1; SMN2 | |
| SCHEMBL11832170 | 0.83 | KMT2A (0.57) | LMNATDP1GSK3BF3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107526-B1 | TOPICAL ANHYDROUS FILL FORMULATION FOR ULTRAVIOLET FILTERS | SCHERER TECHNOLOGIES LLC R P (US) | 2020-07-29 | — | — | EP | claimed |
| EP-2675453-B1 | METHODS FOR CONTROLLING PAIN IN CANINES USING A TRANSDERMAL SOLUTION OF FENTANYL | ELANCO US INC (US) | 2018-08-08 | — | — | EP | claimed |
| US-20170172895-A1 | Topical Anhydrous Fill Formulation For Ultraviolet Filters | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2017-06-22 | — | — | US | claimed |
| US-20170128462-A1 | METHODS FOR TREATING FEMALE SEXUAL DYSFUNCTION WHILE DECREASING CARDIOVASCULAR RISK | ANI PHARMACEUTICALS, INC. | 2017-05-11 | — | — | US | claimed |
| EP-3107526-A1 | TOPICAL ANHYDROUS FILL FORMULATION FOR ULTRAVIOLET FILTERS | R.P. Scherer Technologies, LLC (US) | 2016-12-28 | — | — | EP | claimed |
| WO-2015126874-A1 | TOPICAL ANHYDROUS FILL FORMULATION FOR ULTRAVIOLET FILTERS | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2015-08-27 | — | — | WO | claimed |
| EP-2675453-A1 | METHODS FOR CONTROLLING PAIN IN CANINES USING A TRANSDERMAL SOLUTION OF FENTANYL | ELI LILLY AND CO. (US) | 2013-12-25 | — | — | EP | claimed |
| EP-2675454-A1 | METHODS FOR CONTROLLING PAIN IN EQUINES USING A TRANSDERMAL SOLUTION OF FENTANYL | ELI LILLY AND CO. (US) | 2013-12-25 | — | — | EP | claimed |
| US-20120322828-A1 | METHODS FOR CONTROLLING PAIN IN EQUINES USING A TRANSDERMAL SOLUTION OF FENTANYL | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | claimed |
| WO-2012112355-A1 | METHODS FOR CONTROLLING PAIN IN EQUINES USING A TRANSDERMAL SOLUTION OF FENTANYL | ELI LILLY AND COMPANY (US) | 2012-08-23 | — | — | WO | claimed |
| US-6299900-B1 | NON-OCCLUSIVE, PERCUTANEOUS OR TRANSDERMAL DRUG DELIVERY SYSTEM | MONASH UNIVERSITY (AU) | 2001-10-09 | — | — | US | claimed |
| EP-0812309-B1 | PROCESS FOR PREPARATION OF CINNAMATE SUNSCREEN AGENTS | ISP VAN DYK INC (US) | 2000-04-26 | — | — | EP | claimed |
| EP-0901368-A4 | DERMAL PENETRATION ENHANCERS AND DRUG DELIVERY SYSTEMS INVOLVING SAME | UNIV MONASH (AU) | 2000-01-26 | — | — | EP | claimed |
| EP-0901368-A1 | DERMAL PENETRATION ENHANCERS AND DRUG DELIVERY SYSTEMS INVOLVING SAME | MONASH UNIVERSITY (AU) | 1999-03-17 | — | — | EP | claimed |
| EP-0812309-A1 | PROCESS FOR PREPARATION OF CINNAMATE SUNSCREEN AGENTS | ISP Van Dyk Inc. (US) | 1997-12-17 | — | — | EP | claimed |
| WO-1997029735-A1 | DERMAL PENETRATION ENHANCERS AND DRUG DELIVERY SYSTEMS INVOLVING SAME | MONASH UNIVERSITY (AU) | 1997-08-21 | — | — | WO | claimed |
| WO-1996019436-A1 | PROCESS FOR PREPARATION OF CINNAMATE SUNSCREEN AGENTS | ISP VAN DYK INC. (US) | 1996-06-27 | — | — | WO | claimed |
| US-5527947-A | Process for preparation of cinnamate sunscreen agents | ISP VAN DYK INC. (US) | 1996-06-18 | — | — | US | claimed |
| US-4592906-A | Ester of p-dimethylaminocinnamic acid | GRAESSER LABORATORIES, LTD. (GB) | 1986-06-03 | — | — | US | claimed |
| EP-0153089-A1 | Ultra-violet absorbing compounds and compositions containing said compounds | GRAESSER LABORATORIES LIMITED (GB) | 1985-08-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322828-A1 | METHODS FOR CONTROLLING PAIN IN EQUINES USING A TRANSDERMAL SOLUTION OF FENTANYL | OPRL1, OPRK1, S100P | LMNA 3078/4885TDP1 2151/4885APP 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.